Mark Alexander Speaks to Bloomberg News About Antitrust Concerns and Winning Holder Approval of Nasdaq Bid for NYSE
April 11, 2011
After a Nasdaq bid for the NYSE was rejected by the NYSE board, Mark Alexander, a Hartford, Connecticut-based attorney who focuses on antitrust issues at Axinn, spoke with Bloomberg News about Nasdaq CEO Robert Greifeld’s next move to win NYSE holders’ approval despite antitrust concerns. Deutsche Boerse may have an easier time addressing competition concerns than Nasdaq OMX-ICE, said Mark. With Deutsche Boerse, the antitrust issues are manageable because even if regulators can’t be satisfied that whatever issues there are won’t limit competition, you can divest a business. With Nasdaq/NYSE, the antitrust risk is the deal. It appears to be a pretty significant problem and there’s no way to fix it. You can’t sell assets peripheral to the deal, while with Deutsche Boerse the main value of the transaction can still be realized.
The article, entitled, “Nasdaq CEO Greifeld Needs NYSE Holders to Embrace Bid That Board Rejected,” was published by Bloomberg News on April 11, 2011.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
Axinn Advises Thermo Fisher Scientific on Completed $1.075 Billion Sale of Microbiology Business to Astorg
Deals & Cases
Antitrust
Benchmark Litigation Honors Axinn Partners on 2026 “40 & Under List”
Awards & Recognitions
Litigation & Trials
Axinn Partner Rebecca Clegg Named to Hartford Business Journal’s 2026 40 Under Forty
Awards & Recognitions
Intellectual Property
What Happens in Vegas Stays in Vegas: Third Circuit Parts Ways with Ninth Circuit and Reinstates Atlantic City Algorithmic-Pricing Claim
Axinn Viewpoints
Antitrust
What Should Directors Be Asking? Antitrust in the Boardroom
Podcast
Antitrust
Axinn Represents Modular in $4 Billion Acquisition by Qualcomm
Deals & Cases
Antitrust
Will New DOJ Timing Agreement Deliver Faster Merger Clearances?
Axinn Viewpoints
Antitrust
Why U.S. Regulators Are Cracking Down on Private Equity Investments in the Healthcare Sector
Byline Articles
Antitrust
Women Leaders in Life Sciences Law
Speaking Engagement
Litigation & Trials
